As European cannabis regulation continues to evolve, botanical technology company Eybna is doubling down on the continent's market potential. The Israel-founded, globally operating company will be present at ICBC Berlin, where it will demonstrate its BNA™ AI technology platform and its line of Receptor-Specific™ Formulations — proprietary terpene blends engineered to produce targeted, measurable biological effects. Visitors can find the team at booth #346. CEO and co-founder Nadav Eyal will also take part in a panel discussion during the event.
"Our booth will showcase our ability to customize formulations to clients' aroma, functionality, and market requirements," said Victoria Dang, Eybna's Head of Business Development. The company's all-natural, GMP-certified ingredients are designed to deliver consistent biological outcomes — including effects such as calm, focus, sleep, and uplift — across product categories including vapes, pre-rolls, edibles, and beverages.
© Eybna
Unlike conventional terpene suppliers, whose ingredients are used primarily as aroma and flavor enhancers, Eybna positions its Receptor-Specific™ Formulations as functional ingredients with measurable outcomes. The distinction matters as brands look to differentiate in increasingly competitive markets. "With the combination of specific terpenes, our Receptor-Specific™ Formulations provide measurable outcomes," Dang said.
Europe is a central focus for the company's growth strategy. With operations in Germany, the USA, and Israel, Eybna holds both FSSC and GMP certifications, providing the production reliability and cross-border formulation support that EU-market operators increasingly require. "As regulations continue to change, licensees and manufacturers need reliable, scalable solutions to produce consistent products for the EU market," Dang said.
Regulatory fragmentation across Europe remains a key challenge the company navigates on behalf of its clients. "One of the biggest challenges in Europe is that cannabis regulation differs widely by country, with each EU member state or European country setting its own rules for medical, recreational, and CBD products," Dang noted. "This patchwork framework creates complexity for companies trying to operate across borders." Rather than waiting on regulatory alignment, Eybna sees the industry itself as having a role to shape it. "Those of us in the industry today can collaborate on unified, evidence-based standards, share data demonstrating public health and economic benefits, and engage policymakers with responsible, compliance-first proposals," Dang said.
ICBC Berlin represents a strategic platform for Eybna to connect with European operators and showcase how science-backed formulation technology can address both product consistency and regulatory compliance challenges. Interested attendees can meet the Eybna team at booth #346.
For more information:
Eybna
eybna.com
